title: [Status quo and prospects for systemic therapy of atopic dermatitis. Biologics ante portas].
abstract: Currently the only approved drug available for the systemic therapy of atopic dermatitis is cyclosporine; however, based on current data from published studies, azathioprine, methotrexate, and mycophenolate mofetil or mycophenolic acid can be administered off-label. Some biologics on the market that have been approved for other indications (ustekinumab, rituximab, tocilizumab) have been successfully used in a few patients with atopic dermatitis. The world's first prospective controlled studies with the biologic human anti-IL4R antibody dupilumab for the indication "atopic dermatitis" were published in 2014. These motivated (1) to extend the studies to dupilumab and (2) to clinically test antagonization of other target molecules of TH2 polarized, atopic inflammation, e.g., IL-13, IL-31, IL-22, TSLP, and CRTH2. A number of clinical trials are currently recruiting in this area and will provide interesting new insights for future therapeutic approaches in atopic dermatitis.
authors: Klinik und Poliklinik für Dermatologie und Allergologie, Biedersteinerstraße 29, 80802, München, Deutschland.
authors: T
authors: T
authors: Biedermann
authors: T
authors: T
authors: Werfel
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001688:Biological Products / Q000627:therapeutic use*; D003876:Dermatitis, Atopic / Q000188:drug therapy*; D015195:Drug Design; D005544:Forecasting; D005858:Germany; D058990:Molecular Targeted Therapy / Q000639:trends*
chemical_list: D000911:Antibodies, Monoclonal; D001688:Biological Products
references: J Allergy Clin Immunol. 2011 Nov;128(5):1128-30
references: 21962991
references: Allergy Asthma Proc. 2008 Sep-Oct;29(5):530-7
references: 18926061
references: Int Arch Allergy Immunol. 2013;160(1):18-26
references: 22948028
references: J Am Acad Dermatol. 2011 Jun;64(6):1074-84
references: 21458107
references: Br J Dermatol. 2008 Dec;159(6):1357-63
references: 18795916
references: J Allergy Clin Immunol. 2008 Jan;121(1):122-8
references: 18206507
references: J Dtsch Dermatol Ges. 2009 Jan;7 Suppl 1:S1-46
references: 19138304
references: J Allergy Clin Immunol. 2009 Sep;124(3 Suppl 2):R2-6
references: 19720209
references: Cell. 2013 Oct 10;155(2):285-95
references: 24094650
references: Expert Opin Investig Drugs. 2015 Jan;24(1):61-68
references: 25201033
references: J Eur Acad Dermatol Venereol. 2012 Sep;26(9):1176-93
references: 22813359
references: J Invest Dermatol. 2009 Aug;129(8):1878-91
references: 19357709
references: Acta Derm Venereol. 2007;87(2):100-11
references: 17340015
references: Allergy. 2015 Jan;70(1):6-11
references: 25074686
references: J Allergy Clin Immunol. 2014 Dec;134(6):1293-1300
references: 25482871
references: J Allergy Clin Immunol. 2014 Jul;134(1):92-9
references: 24698321
references: N Engl J Med. 2011 Jul 21;365(3):231-8
references: 21774711
references: J Allergy Clin Immunol. 2008 Jun;121(6):1515-6; author reply 1516-7
references: 18410962
references: J Allergy Clin Immunol. 2007 Nov;120(5):1223-5
references: 17936892
references: N Engl J Med. 2014 Jul 10;371(2):130-9
references: 25006719
references: J Am Acad Dermatol. 2014 Oct;71(4):814-21
references: 24906613
references: J Dtsch Dermatol Ges. 2009 May;7(5):474-9
references: 19302564
references: J Dtsch Dermatol Ges. 2010 Dec;8(12):990-8
references: 20678148
references: J Invest Dermatol. 2014 Jan;134(1):96-104
references: 23812300
references: J Dtsch Dermatol Ges. 2003 Apr;1(4):259-72
references: 16285480
references: Semin Cutan Med Surg. 2013 Sep;32(3):132-9
references: 24175400
references: Z Rheumatol. 2013 Jun;72(5):423-8
references: 23743984
references: Int Arch Allergy Immunol. 2006;141(3):290-4
references: 16931891
references: N Engl J Med. 2013 Jun 27;368(26):2455-66
references: 23688323
references: Int J Dermatol. 2012 Jan;51(1):115-6
references: 22182388
references: J Am Acad Dermatol. 2006 Jan;54(1):68-72
references: 16384758